Study confirms that protease inhibitor cocktail can delay HIV disease progression and death. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Study confirms that protease inhibitor cocktail can delay HIV disease progression and death. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

NIAID AIDS Agenda. 1997 Mar;:1-2. Unique Identifier : AIDSLINE AIDS/97702455
Randall P

Abstract: A study funded by the National Institute of Allergy and Infectious Diseases (NIAID) has shown that combination protease inhibitor therapy plus two nucleoside analogues is significantly more effective than using two nucleoside analogs alone in reducing the occurrence of AIDS-defining illnesses and death. Since preliminary results of ACTG 320 provided such strong evidence, the board recommended early termination of enrollment and study closure.
Keywords: Anti-HIV Agents/*THERAPEUTIC USE CD4 Lymphocyte Count Clinical Trials Disease Progression Drug Therapy, Combination HIV Infections/*DRUG THERAPY/MORTALITY HIV Protease Inhibitors/*THERAPEUTIC USE Human Indinavir/*THERAPEUTIC USE Lamivudine/*THERAPEUTIC USE Reverse Transcriptase Inhibitors/*THERAPEUTIC USE United States Zidovudine/*THERAPEUTIC USE NEWSLETTER ARTICLEKWDanti-hivagents/KWDtherapeuticusecd4lymphocytecountclinicaltrialsdiseaseprogressiondrugtherapy,combinationhivinfections/KWDdrugtherapy/mortalityhivproteaseinhibitors/KWDtherapeuticusehumanindinavir/KWDtherapeuticuselamivudine/KWDtherapeuticusereversetranscriptaseinhibitors/KWDtherapeuticuseunitedstateszidovudine/KWDtherapeuticusenewsletterarticle
970830
M9781268

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .